Advertisement

Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2017.
        CA Cancer J Clin. 2017; 67: 7-30
      1. American Cancer Society. Breast cancer facts & figures 2013-2014, 2013.

        • DeSantis C.E.
        • Fewewa S.A.
        • Goding Sauer A.
        • et al.
        Breast cancer statistics, 2015: convergence of incidence rates between black and white women.
        CA Cancer J Clin. 2016; 66: 31-42
        • Collaborative Group on Hormonal Factors in Breast Cancer
        Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.
        Lancet. 2001; 358: 1389-1399
        • van der Groep P.
        • Bouter A.
        • van der Zanden R.
        • et al.
        Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
        J Clin Pathol. 2006; 59: 611-617
        • Kleibl Z.
        • Kristensen V.N.
        Women at high risk of breast cancer: molecular characteristics, clinical presentation and management.
        Breast. 2016; 28: 136-144
        • McCarthy A.M.
        • Bristol M.
        • Domchek S.M.
        • et al.
        Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer.
        J Clin Oncol. 2016; 34: 2610-2618
        • Cragun D.
        • Weidner A.
        • Lewis C.
        • et al.
        Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
        Cancer. 2017; 123: 2497-2505
        • Forman A.D.
        • Hall M.J.
        Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
        Breast J. 2009; 15: S56-S62
      2. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian (Version 2.2017). Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed March 23, 2017.

        • Moyer V.A.
        • US Preventive Services Task Force
        Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2014; 160: 271-281
      3. Available at: https://www.facs.org/quality-programs/napbc/standards/components.

        • American Society of Clinical Oncology
        American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
        J Clin Oncol. 2003; 21: 2397-2406
        • Berliner J.L.
        • Fay A.M.
        Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.
        J Genet Couns. 2007; 16: 241-260
        • Pal T.
        • Vadaparampil S.T.
        Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.
        Cancer Control. 2012; 19: 255-266
        • Robson M.E.
        • Bradbury A.R.
        • Arun B.
        • et al.
        American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
        J Clin Oncol. 2015; 33: 3660-3667
        • LaDuca H.
        • Stuenkel A.J.
        • Dolinsky J.S.
        • et al.
        Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.
        Genet Med. 2014; 16: 830-837
        • Kurian A.W.
        • Hare E.E.
        • Mills M.A.
        • et al.
        Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.
        J Clin Oncol. 2014; 32: 2001-2009
        • van Os N.J.
        • Roeleveld N.
        • Weemaes C.M.
        • et al.
        Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis, and evidence-based guideline.
        Clin Genet. 2016; 90: 105-117
        • Tung N.
        • Domchek S.M.
        • Stadler Z.
        • et al.
        Counselling framework for moderate-penetrance cancer-susceptibility mutations.
        Nat Rev Clin Oncol. 2016; 13: 581-588
        • Hall M.J.
        • Reid J.E.
        • Burbidge L.A.
        • et al.
        BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
        Cancer. 2009; 115: 2222-2233
        • Pal T.
        • Bonner D.
        • Kim J.
        • et al.
        Early onset breast cancer in a registry-based sample of African American women: BRCA mutation prevalence, and other personal and system-level clinical characteristics.
        Breast J. 2013; 19: 189-192
        • Slavin T.P.
        • Niell-Swiller M.
        • Solomon I.
        • et al.
        Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management.
        Front Oncol. 2015; 5: 208
        • King M.-C.
        “The race” to clone BRCA1.
        Science. 2014; 343: 1462-1465
        • Risch H.A.
        • McLaughlin J.R.
        • Cole D.E.
        • et al.
        Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
        Am J Hum Genet. 2001; 68: 700-710
        • Narod S.A.
        • Offit K.
        Prevention and management of hereditary breast cancer.
        J Clin Oncol. 2005; 23: 1656-1663
        • Ford D.
        • Easton D.F.
        • Bishop D.T.
        • et al.
        Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
        Lancet. 1994; 343: 692-695
        • Ford D.
        • Easton D.F.
        • Stratton M.
        • et al.
        Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
        Am J Hum Genet. 1998; 62: 676-689
        • Chen S.
        • Parmigiani G.
        Meta-analysis of BRCA1 and BRCA2 penetrance.
        J Clin Oncol. 2007; 25: 1329-1333
        • Weitzel J.N.
        • Lagos V.I.
        • Cullinane C.A.
        • et al.
        Limited family structure and BRCA gene mutation status in single cases of breast cancer.
        JAMA. 2007; 297: 2587-2595
        • American College of Obstetricians and Gynecologists
        • ACOG Committee on Practice Bulletins–Gynecology
        • ACOG Committee on Genetics
        • Society of Gynecologic Oncologists
        ACOG practice bulletin no. 103: hereditary breast and ovarian cancer syndrome.
        Obstet Gynecol. 2009; 113: 957-966
        • Whittemore A.S.
        Risk of breast cancer in carriers of BRCA gene mutations.
        N Engl J Med. 1997; 337: 788-789
        • Fostira F.
        • Tsitlaidou M.
        • Papadimitriou C.
        • et al.
        Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group study.
        Breast Cancer Res Treat. 2012; 134: 353-362
        • Gonzalez-Angulo A.M.
        • Timms K.M.
        • Liu S.
        • et al.
        Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
        Clin Cancer Res. 2011; 17: 1082-1089
        • Antoniou A.C.
        • Hardy R.
        • Walker L.
        • et al.
        Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
        J Med Genet. 2008; 45: 425-431
        • Hartmann L.C.
        • Sellers T.A.
        • Schaid D.J.
        • et al.
        Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
        J Natl Cancer Inst. 2001; 93: 1633-1637
        • Rebbeck T.R.
        • Friebel T.
        • Lynch H.T.
        • et al.
        Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
        J Clin Oncol. 2004; 22: 1055-1062
        • Meijers-Heijboer H.
        • van Geel B.
        • van Putten W.L.
        • et al.
        Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
        N Engl J Med. 2001; 345: 159-164
        • Mavaddat N.
        • Peock S.
        • Frost D.
        • et al.
        Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
        J Natl Cancer Inst. 2013; 105: 812-822
        • Gronwald J.
        • Tung N.
        • Foulkes W.D.
        • et al.
        Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
        Int J Cancer. 2006; 118: 2281-2284
        • Narod S.A.
        • Brunet J.S.
        • Ghadirian P.
        • et al.
        Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
        Lancet. 2000; 356: 1876-1881
        • Kauff N.D.
        • Satagopan J.M.
        • Robson M.E.
        • et al.
        Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
        N Engl J Med. 2002; 346: 1609-1615
        • Rebbeck T.R.
        • Lunch H.T.
        • Neuhausen S.L.
        • et al.
        Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
        N Engl J Med. 2002; 346: 1616-1622
        • Modan B.
        • Hartge P.
        • Hirsh-Yechezkel G.
        • et al.
        Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
        N Engl J Med. 2001; 345: 235-240
        • Narod S.A.
        • Risch H.
        • Moslehi R.
        • et al.
        Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
        N Engl J Med. 1998; 339 (55): 424-428
        • Narod S.A.
        • Dubé M.P.
        • Klihn J.
        • et al.
        Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
        J Natl Cancer Inst. 2002; 94: 1773-1779
        • Domagala P.
        • Hybiak J.
        • Rys J.
        • et al.
        Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
        Oncotarget. 2016; 7: 68662-68673
        • Schouten P.C.
        • Dackus G.M.
        • Marchetti S.
        • et al.
        A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
        Trials. 2016; 17: 293
        • Sidransky D.
        • Tokino T.
        • Helzlsouer K.
        • et al.
        Inherited p53 gene mutations in breast cancer.
        Cancer Res. 1992; 52: 2984-2986
        • Mai P.L.
        • Best A.F.
        • Peters J.A.
        • et al.
        Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
        Cancer. 2016; 122: 3673-3681
        • Lane D.P.
        Cancer. p53, guardian of the genome.
        Nature. 1992; 358: 15-16
        • Levine A.J.
        p53, the cellular gatekeeper for growth and division.
        Cell. 1997; 88: 323-331
        • Gonzalez K.D.
        • Noltner K.A.
        • Buzin C.H.
        • et al.
        Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations.
        J Clin Oncol. 2009; 27: 1250-1256
        • Li F.P.
        • Fraumeni Jr., J.F.
        • Mulvihill J.J.
        • et al.
        A cancer family syndrome in twenty-four kindreds.
        Cancer Res. 1988; 48: 5358-5362
        • Nichols K.E.
        • Malkin D.
        • Garber J.E.
        • et al.
        Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
        Cancer Epidemiol Biomarkers Prev. 2001; 10: 83-87
        • Hwang S.J.
        • Lozano G.
        • Amos C.I.
        • et al.
        Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk.
        Am J Hum Genet. 2003; 72: 975-983
        • Chompret A.
        • Abel A.
        • Stoppa-Lyonnet D.
        • et al.
        Sensitivity and predictive value of criteria for p53 germline mutation screening.
        J Med Genet. 2001; 38: 43-47
        • Birch J.M.
        • Hartley A.L.
        • Tricker K.J.
        • et al.
        Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
        Cancer Res. 1994; 54: 1298-1304
        • Varley J.M.
        • Evans D.G.
        • Birch J.M.
        Li-Fraumeni syndrome—a molecular and clinical review.
        Br J Cancer. 1997; 76: 1-14
        • Frebourg T.
        • Barbier N.
        • Yan Y.X.
        • et al.
        Germ-line p53 mutations in 15 families with Li- Fraumeni syndrome.
        Am J Hum Genet. 1995; 56: 608-615
        • Brugières L.
        • Gardes M.
        • Moutou C.
        • et al.
        Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer.
        Cancer Res. 1993; 53: 452-455
        • Varley J.M.
        • McGown G.
        • Thorncraft M.
        • et al.
        Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
        Cancer Res. 1997; 57: 3245-3252
        • Chompret A.
        • Brugières L.
        • Ronsin M.
        • et al.
        P53 germline mutations in childhood cancers and cancer risk for carrier individuals.
        Br J Cancer. 2000; 82: 1932-1937
        • Le Bihan C.
        • Moutou C.
        • Brugières L.
        • et al.
        ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data.
        Genet Epidemiol. 1995; 12: 13-25
        • Wu C.C.
        • Shete S.
        • Amos C.I.
        • et al.
        Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
        Cancer Res. 2006; 66: 8287-8292
        • Hisada M.
        • Garber J.E.
        • Fung C.Y.
        • et al.
        Multiple primary cancers in families with Li-Fraumeni syndrome.
        J Natl Cancer Inst. 1998; 90: 606-611
        • Villani A.
        • Tabori U.
        • Schiffman J.
        • et al.
        Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
        Lancet Oncol. 2011; 12: 559-567
        • Masciari S.
        • Van den Abbeele A.D.
        • Diller L.R.
        • et al.
        F18-Fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
        JAMA. 2008; 299: 1315-1319
        • Monsalve J.
        • Kapur J.
        • Malkin D.
        • et al.
        Radiographics: a review. Imaging of cancer predisposition syndromes in children. vol. 31(1). Radiological Society of North America, 2011: 263-280
        • Henry E.
        • Villalobos V.
        • Million L.
        • et al.
        Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome.
        J Natl Compr Canc Netw. 2012; 10: 939-942
        • Kast K.
        • Krause M.
        • Schuler M.
        • et al.
        Late onset Li-Fraumeni syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.
        BMC Cancer. 2012; 12: 217
        • Bougeard G.
        • Renaux-Petel M.
        • Flaman J.M.
        • et al.
        Revisiting Li-Fraumeni syndrome from TP53 mutation carriers.
        J Clin Oncol. 2015; 33: 2345-2352
        • Pilarski R.
        Cowden syndrome: a critical review of the clinical literature.
        J Genet Couns. 2009; 18: 13-27
        • Eng C.
        PTEN hamartoma tumor syndrome (PTHS).
        GeneReviews. 2009;
        • Pilarski R.
        • Stephens J.A.
        • Noss R.
        • et al.
        Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.
        J Med Genet. 2011; 48: 505-512
        • Eng C.
        PTEN hamartoma tumor syndrome (PTHS).
        GeneReviews. 2001;
        • Nelen M.R.
        • Padberg G.W.
        • Peeters E.A.
        • et al.
        Localization of the gene for Cowden disease to chromosome 10q22-23.
        Nat Genet. 1996; 13: 114-116
        • Pilarski R.
        • Eng C.
        Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome.
        J Med Genet. 2004; 41: 323-326
        • Mester J.
        • Charis E.
        PTEN hamartoma tumor syndrome.
        Handb Clin Neurol. 2015; 132: 129-137
        • Tan M.H.
        • Mester J.
        • Peterson C.
        • et al.
        A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.
        Am J Hum Genet. 2011; 88: 42-56
        • Bennett K.L.
        • Mester J.
        • Eng C.
        Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
        JAMA. 2010; 304: 2724-2731
        • Hobert J.A.
        • Eng C.
        PTEN hamartoma tumor syndrome: an overview.
        Genet Med. 2009; 11: 687-694
        • Tan M.H.
        • Mester J.L.
        • Ngeow J.
        • et al.
        Lifetime cancer risks in individuals with germline PTEN mutations.
        Clin Cancer Res. 2012; 18: 400-407
        • Nieuwenhuis M.H.
        • Kets C.M.
        • Murphy-Ryan M.
        • et al.
        Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome.
        Fam Cancer. 2014; 13: 57-63
        • Bubien V.
        • Bonnet F.
        • Brouste V.
        • et al.
        High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
        J Med Genet. 2013; 50: 255-263
        • Ngeow J.
        • Eng C.
        PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
        Methods. 2015; 77-78: 11-19
        • Xia B.
        • Sheng Q.
        • Nakanishi K.
        • et al.
        Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
        Mol Cell. 2006; 22: 719-729
        • Antoniou A.C.
        • Casadei S.
        • Heikkinen T.
        • et al.
        Breast cancer risks in families with mutations in PALB2.
        N Engl J Med. 2014; 7: 497-506
        • Sy S.M.
        • Huen M.S.
        • Zhu Y.
        • et al.
        PALB2 regulates recombinational repair through chromatin association and oligomerization.
        J Biol Chem. 2009; 284: 18302-18310
        • Zhang F.
        • Ma J.
        • Wu J.
        • et al.
        PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
        Curr Biol. 2009; 19: 524-529
        • Cybulski C.
        • Kluzniak W.
        • Huzarski T.
        • et al.
        Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.
        Lancet Oncol. 2015; 16: 638-644
        • Basham V.M.
        • Lipscombe J.M.
        • Ward J.M.
        • et al.
        BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.
        Breast Cancer Res. 2002; 4: R2
        • Norquist B.M.
        • Harrell M.I.
        • Brady M.F.
        • et al.
        Inherited mutations in women with ovarian carcinoma.
        JAMA Oncol. 2016; 2: 482-490
        • Guilford P.
        • Hopkins J.
        • Harraway J.
        • et al.
        E-cadherin germline mutations in familial gastric cancer.
        Nature. 1998; 392: 402-405
        • Keller G.
        • Vogelsang H.
        • Becker I.
        • et al.
        Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation.
        Am J Pathol. 1999; 155: 337-342
        • Kaurah P.
        • MacMillan A.
        • Boyd N.
        • et al.
        Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.
        JAMA. 2007; 297: 2360-2372
        • Pharoah P.D.
        • Guilford P.
        • Caldas C.
        Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families.
        Gastroenterology. 2001; 121: 1348-1353
        • van der Post R.S.
        • Vogelaar I.P.
        • Carneiro F.
        • et al.
        Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.
        J Med Genet. 2015; 52: 361-374
        • Choi M.
        • Kipps T.
        • Kurzrock R.
        ATM mutations in cancer: therapeutic implications.
        Mol Cancer Ther. 2016; 15: 1781-1791
        • Renwick A.
        • Thompson D.
        • Seal S.
        • et al.
        ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.
        Nat Genet. 2006; 38: 873-875
        • Thompson D.
        • Duedal S.
        • Kirner J.
        • et al.
        Cancer risks and mortality in heterozygous ATM mutation carriers.
        J Natl Cancer Inst. 2005; 97: 813-822
        • Ahmed M.
        • Rahman N.
        ATM and breast cancer susceptibility.
        Oncogene. 2006; 25: 5906-5911
        • Morrell D.
        • Cromartie E.
        • Swift M.
        Mortality and cancer incidence in 263 patients with ataxia-telangiectasia.
        J Natl Cancer Inst. 1986; 77: 89-92
        • Bueno R.C.
        • Canevari R.A.
        • Villacis R.A.
        • et al.
        ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.
        Ann Oncol. 2014; 25: 69-75
        • Walsh T.
        • Casadei S.
        • Coats K.H.
        • et al.
        Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
        JAMA. 2006; 295: 1379-1388
        • Gage M.
        • Wattendorf D.
        • Henry L.R.
        Translational advances regarding hereditary breast cancer syndromes.
        J Surg Oncol. 2012; 105: 444-451
        • Cybulski C.
        • Wokolorczyk D.
        • Jakubowska A.
        • et al.
        Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
        J Clin Oncol. 2011; 29: 3747-3752
        • Weischer M.
        • Bojesen S.E.
        • Ellervik C.
        • et al.
        CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
        J Clin Oncol. 2008; 26: 542-548
        • Naslund-Koch C.
        • Nordestgaard B.G.
        • Bojesen S.E.
        Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study.
        J Clin Oncol. 2016; 34: 1208-1216
        • Schmidt M.K.
        • Hogervorst F.
        • van Hien R.
        • et al.
        Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers.
        J Clin Oncol. 2016; 34: 2750-2760
        • Cybulski C.
        • Huzarski T.
        • Byrski T.
        • et al.
        Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.
        Clin Genet. 2009; 75: 72-78
        • Loveday C.
        • Turnbull C.
        • Ruark E.
        • et al.
        Germline RAD51C mutations confer susceptibility to ovarian cancer.
        Nat Genet. 2012; 44: 475-476
        • Song H.
        • Dicks E.
        • Ramus S.J.
        • et al.
        Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population.
        J Clin Oncol. 2015; 33: 2901-2907